REFRESH
A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension
- Stadium
- klaar
- Middel
- Firibastat
- Populatie
- Primaire preventie coronairlijden
- Fase
- III
- First Patient In
- 30 mei 2022
- Last Patient In
- 28 oktober 2022
- Last Patient Last Visit
- 15 november 2022
Studiedirecteur
drs. H.G.R. Dorman
Cardioloog
Contact Kantoor
